EGFR Knockout A2780 Polyclonal Cells comprise a CRISPR/Cas9-mediated gene-disrupted polyclonal cell population derived from A2780 human ovarian carcinoma cells. The targeted disruption of the EGFR gene generates a loss-of-function model that enables precise dissection of EGFR-dependent signaling pathways in an epithelial ovarian cancer background while maintaining the genetic heterogeneity inherent to polyclonal populations.
The parental A2780 cell line was established from an untreated patient with ovarian carcinoma and exhibits characteristic epithelial morphology. These cells are a widely employed model of high-grade serous ovarian cancer, retaining key oncogenic signaling cascades and clinically relevant drug sensitivities, including sensitivity to platinum-based chemotherapeutics. Their intact TP53 status and robust growth characteristics make them suitable for functional genomics and tumor biology studies.
EGFR encodes a transmembrane receptor tyrosine kinase that orchestrates critical cellular processes. Upon binding by cognate ligands??including EGF, TGF-??, amphiregulin, and HB-EGF??the receptor dimerizes, autophosphorylates, and recruits adaptor proteins such as Grb2, SHC1, and GAB1. These events trigger downstream signaling through RAS-RAF-MEK-ERK, PI3K-AKT-mTOR, and JAK-STAT cascades, culminating in the activation of transcription factors and effector molecules including MYC, STAT3, and CCND1 (cyclin D1). Additional pathway modulators like SOS, PLC??1, and CBL further fine-tune signaling output, ultimately promoting cell proliferation, survival, and migration.
In the context of A2780 ovarian carcinoma cells, EGFR signaling is frequently dysregulated and contributes to malignant phenotypes. CRISPR/Cas9-mediated disruption of EGFR abrogates ligand-induced activation of ERK1/2 and AKT, thereby attenuating pro-survival and proliferative signals. This knockout model permits rigorous evaluation of EGFR dependency in ovarian cancer, facilitates discovery of bypass signaling mechanisms, and provides a baseline for assessing compensatory network rewiring following targeted therapy.
These polyclonal knockout cells are ideally suited for functional genomics, drug target validation, and signal transduction research. Typical experimental paradigms include western blot analysis of EGFR and phospho-ERK, RT-qPCR quantitation of downstream targets (e.g., MYC, CCND1), MTT/XTT proliferation assays, Transwell migration/invasion studies, and caspase-3/7 apoptosis measurements. They can also be utilized in tumor xenograft models and in vitro drug sensitivity profiling with EGFR tyrosine kinase inhibitors such as gefitinib or erlotinib. For technical inquiries, please contact Ascent Research.
